Literature DB >> 23629656

Nuclear corepressors mediate the repression of phospholipase A2 group IIa gene transcription by thyroid hormone.

Pragya Sharma1, Shalini Thakran1, Xiong Deng2, Marshall B Elam2, Edwards A Park3.   

Abstract

Secretory phospholipase A2 group IIa (PLA2g2a) is associated with inflammation, hyperlipidemia, and atherogenesis. Transcription of the PLA2g2a gene is induced by multiple cytokines. Here, we report the surprising observation that thyroid hormone (T3) inhibited PLA2g2a gene expression in human and rat hepatocytes as well as in rat liver. Moreover, T3 reduced the cytokine-mediated induction of PLA2g2a, suggesting that the thyroid status may modulate aspects of the inflammatory response. In an effort to dissect the mechanism of repression by T3, we cloned the PLA2g2a gene and identified a negative T3 response element in the promoter. This T3 receptor (TRβ)-binding site differed considerably from consensus T3 stimulatory elements. Using in vitro and in vivo binding assays, we found that TRβ bound directly to the PLA2g2a promoter as a heterodimer with the retinoid X receptor. Knockdown of nuclear corepressor or silencing mediator for retinoid and thyroid receptors by siRNA blocked the T3 inhibition of PLA2g2a. Using chromatin immunoprecipitation assays, we showed that nuclear corepressor and silencing mediator for retinoid and thyroid receptors were associated with the PLA2g2a gene in the presence of T3. In contrast with the established role of T3 to promote coactivator association with TRβ, our experiments demonstrate a novel inverse recruitment mechanism in which liganded TRβ recruits corepressors to inhibit PLA2g2a expression.

Entities:  

Keywords:  Carnitine Palmitoyltransferase; Corepressor Transcription; Liver; Nuclear Receptors; Phospholipase A; Thyroid Hormone; Thyroid Hormone Receptor; Transcriptional Regulation

Mesh:

Substances:

Year:  2013        PMID: 23629656      PMCID: PMC3675570          DOI: 10.1074/jbc.M112.445569

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  71 in total

1.  Direct interdomain interactions can mediate allosterism in the thyroid receptor.

Authors:  Balananda-Dhurjati K Putcha; Elias J Fernandez
Journal:  J Biol Chem       Date:  2009-06-26       Impact factor: 5.157

2.  A role for helix 3 of the TRbeta ligand-binding domain in coactivator recruitment identified by characterization of a third cluster of mutations in resistance to thyroid hormone.

Authors:  T N Collingwood; R Wagner; C H Matthews; R J Clifton-Bligh; M Gurnell; O Rajanayagam; M Agostini; R J Fletterick; P Beck-Peccoz; W Reinhardt; G Binder; M B Ranke; A Hermus; R D Hesch; J Lazarus; P Newrick; V Parfitt; P Raggatt; F de Zegher; V K Chatterjee
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

3.  The interaction between nuclear receptor corepressor and histone deacetylase 3 regulates both positive and negative thyroid hormone action in vivo.

Authors:  Seo-Hee You; Xiaohui Liao; Roy E Weiss; Mitchell A Lazar
Journal:  Mol Endocrinol       Date:  2010-04-28

4.  Protection against diet-induced obesity and obesity- related insulin resistance in Group 1B PLA2-deficient mice.

Authors:  Kevin W Huggins; Amy C Boileau; David Y Hui
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-11       Impact factor: 4.310

5.  Protein kinase A-dependent stimulation of rat type II secreted phospholipase A(2) gene transcription involves C/EBP-beta and -delta in vascular smooth muscle cells.

Authors:  C Couturier; V Antonio; A Brouillet; G Béréziat; M Raymondjean; M Andréani
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-12       Impact factor: 8.311

6.  Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids.

Authors:  N Leitinger; A D Watson; S Y Hama; B Ivandic; J H Qiao; J Huber; K F Faull; D S Grass; M Navab; A M Fogelman; F C de Beer; A J Lusis; J A Berliner
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-05       Impact factor: 8.311

7.  Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist.

Authors:  Edward E Cable; Patricia D Finn; Jeffrey W Stebbins; Jinzhao Hou; Bruce R Ito; Paul D van Poelje; David L Linemeyer; Mark D Erion
Journal:  Hepatology       Date:  2009-02       Impact factor: 17.425

Review 8.  Molecular aspects of thyroid hormone actions.

Authors:  Sheue-Yann Cheng; Jack L Leonard; Paul J Davis
Journal:  Endocr Rev       Date:  2010-01-05       Impact factor: 19.871

Review 9.  Thyroid hormone and atherosclerosis.

Authors:  Toshihiro Ichiki
Journal:  Vascul Pharmacol       Date:  2009-10-04       Impact factor: 5.773

10.  Functional analysis of two PLA2G2A variants associated with secretory phospholipase A2-IIA levels.

Authors:  Holly J Exeter; Lasse Folkersen; Jutta Palmen; Anders Franco-Cereceda; Jackie A Cooper; Anastasia Z Kalea; Ferdinand Van't Hooft; Per Eriksson; Steve E Humphries; Philippa J Talmud
Journal:  PLoS One       Date:  2012-07-17       Impact factor: 3.240

View more
  6 in total

Review 1.  Allosteric pathways in nuclear receptors - Potential targets for drug design.

Authors:  Elias J Fernandez
Journal:  Pharmacol Ther       Date:  2017-10-31       Impact factor: 12.310

2.  Thyroid hormone status regulates the expression of secretory phospholipases.

Authors:  Pragya Sharma; Tania Levesque; Eric Boilard; Edwards A Park
Journal:  Biochem Biophys Res Commun       Date:  2014-01-16       Impact factor: 3.575

3.  Impaired Repressor Function in SUMOylation-Defective Thyroid Hormone Receptor Isoforms.

Authors:  Joachim M Weitzel
Journal:  Eur Thyroid J       Date:  2016-08-04

4.  Secretory phospholipase A2 group IIA modulates insulin sensitivity and metabolism.

Authors:  Michael S Kuefner; Kevin Pham; Jeanna R Redd; Erin J Stephenson; Innocence Harvey; Xiong Deng; Dave Bridges; Eric Boilard; Marshall B Elam; Edwards A Park
Journal:  J Lipid Res       Date:  2017-06-29       Impact factor: 5.922

5.  AMPK Signaling Involvement for the Repression of the IL-1β-Induced Group IIA Secretory Phospholipase A2 Expression in VSMCs.

Authors:  Khadija El Hadri; Chantal Denoyelle; Lucas Ravaux; Benoit Viollet; Marc Foretz; Bertrand Friguet; Mustapha Rouis; Michel Raymondjean
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

6.  Modulation of gene expression by 3-iodothyronamine: genetic evidence for a lipolytic pattern.

Authors:  Veronica Mariotti; Erika Melissari; Caterina Iofrida; Marco Righi; Manuela Di Russo; Riccardo Donzelli; Alessandro Saba; Sabina Frascarelli; Grazia Chiellini; Riccardo Zucchi; Silvia Pellegrini
Journal:  PLoS One       Date:  2014-11-07       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.